Raia Drogasil S/A (RADL3.SA) Osake Kurssi
Raia Drogasil S/A Kurssi
Liikevaihto on kasvanut 24,6 % vuodessa viimeisten 19 vuoden aikana 44,25 Mrd. BRL:een. Osakekohtainen tulos on kasvanut 18,8 % vuodessa viimeisten 19 vuoden aikana. Raia Drogasil S/An nettomarginaali on nyt 2,9 %, pääosin vakaa 3,1 %:sta muutama vuosi sitten. Raia Drogasil S/An osinkotuotto on tällä hetkellä noin 2,11 %. Jakosuhde on noin 59 % tuloksesta. Osinko on kasvanut 7,8 % vuodessa viimeisten 19 vuoden aikana. Analyytikoiden mediaanitavoitehinta on 27,00 BRL, eli yli nykyhintaa 29,3 %. 20 analyytikosta 17 suosittaa ostoa — kokonaiskonsensus on Osta.
Raia Drogasil S/A osakekurssi
Raia Drogasil S/A liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Raia Drogasil S/A -osakkeesta
Raia Drogasil SA is a leading Brazilian retail pharmacy chain specializing in the sale of medications, personal care products, cosmetics, and healthcare items. Its business model revolves around providing a wide range of high-quality products at competitive prices through its extensive network of conveniently located stores. Raia Drogasil SA focuses on delivering exceptional customer service and offers an extensive assortment of both generic and branded products to meet the diverse needs of its customers. By leveraging its strong brand recognition and efficient supply chain, the company has successfully established itself as a trusted name in the pharmaceutical retail industry in Brazil.
Raia Drogasil SA is primarily active in the retail industry, specifically in the pharmaceutical and healthcare sectors.
The main competitors of Raia Drogasil SA in the market include major pharmacy chains such as Panvel, Droga Raia, Pague Menos, and Ultrafarma. They compete with Raia Drogasil SA in terms of market share, store network, and product offerings within the pharmaceutical retail industry. These competitors aim to attract customers with competitive prices, a wide range of products, and convenient store locations, similar to what Raia Drogasil SA offers.
Raia Drogasil SA is a prominent Brazilian retail company specializing in pharmaceutical products. Established in 2011 through the merger of Raia S.A. and Drogasil S.A., the company boasts a rich history and a solid background in the healthcare industry. Raia Drogasil SA operates an extensive network of drugstores across Brazil, providing a wide range of medicines, personal care products, beauty items, and wellness solutions. With a focus on customer satisfaction and convenient accessibility, the company has earned a strong reputation and grown into the largest retail pharmacy chain in the country. Raia Drogasil SA continues to expand its presence and actively contributes to the improvement of healthcare services in Brazil.
Raia Drogasil SA, a leading Brazilian pharmaceutical company, has achieved significant milestones over the years. The company has successfully expanded its retail network, solidifying its position as the largest chain of drugstores in Brazil. Raia Drogasil SA has also made noteworthy acquisitions, such as the purchase of Drogasil, which further enhanced its market presence. In addition, the company has consistently reported strong financial performance and steady revenue growth. Raia Drogasil SA's commitment to innovation and customer satisfaction has earned them numerous accolades, including being recognized as one of the most admired companies in Brazil.
Raia Drogasil SA is primarily present in Brazil.
Raia Drogasil SA embodies a set of core values and a corporate philosophy that define its operations and success. With a commitment to excellence and customer satisfaction, Raia Drogasil SA values integrity, professionalism, and innovation. The company strives to deliver high-quality products and services, ensuring the well-being and health of its customers. Raia Drogasil SA operates with a customer-centric approach, aiming to provide accessible healthcare solutions and personalized care. With a strong emphasis on teamwork and continuous improvement, Raia Drogasil SA fosters a supportive and dynamic work environment. These values and corporate philosophy define Raia Drogasil SA's commitment to exceptional service and its mission to be a leading player in the healthcare industry.
Analyytikot asettavat tällä hetkellä Raia Drogasil S/A-osakkeelle keskimääräisen tavoitehinnan 27,35 BRL (mediaani: 27,00 BRL), mikä merkitsee +31,0 % viimeisimpään hintaan verrattuna. Konsensus perustuu 20 analyytikkoarvioon.
20 analyytikkoa arvioi tällä hetkellä Raia Drogasil S/A-osaketta: 17 suosittaa ostoa, 3 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Raia Drogasil S/A-yhtiöltä 46,03 Mrd. BRL liikevaihtoa ja 0,84 BRL osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Raia Drogasil S/A-osake noteerataan hintaan 3,72 EUR (20,88 BRL).
Raia Drogasil S/A-osake (RADL3.SA) on listattuna 2 pörssissä, muun muassa: B3 (São Paulo) (RADL3.SA).
Raia Drogasil SA is a leading Brazilian retail company specializing in the sale of pharmaceuticals and health products. Founded in 1905 in São Paulo, the company has built a strong presence in Brazil over the years and has become known as a reliable provider of health products and services. The business model of Raia Drogasil SA includes a range of divisions and products tailored to the needs of customers. One of the main divisions of the company is the sale of prescription and generic drugs. Here, the company offers a wide range of prescription and over-the-counter medications, as well as an extensive selection of health and wellness products. In addition to the sale of medications, Raia Drogasil SA's business model also includes other important divisions such as health insurance and pharmacies. The company provides comprehensive healthcare services ranging from prescription medications to assistance in creating nutrition plans and disease prevention. Another important component of Raia Drogasil SA's business model is its commitment to digital transformation. The company utilizes modern technologies to enhance its business processes and provide customers with a seamless and personalized experience. The company's online platform includes a wide range of products and services that can be accessed by customers anytime and anywhere. Raia Drogasil SA is also known for its wide range of private label products. The company develops and produces a variety of health and wellness products such as dietary supplements, vitamins, cosmetic products, sunscreens, and more. These products are available in all company branches and offer customers an affordable alternative to branded products. Another important aspect of Raia Drogasil SA's business model is its commitment to future growth and expansion opportunities. The company pursues an aggressive expansion strategy and plans to further expand its presence in Brazil. Key growth initiatives include opening new branches, expanding the product range, and introducing new technologies. In summary, the business model of Raia Drogasil SA is focused on meeting the growing needs of customers for health products and services. The company relies on a wide range of divisions and products, including medications, health insurance, pharmacies, digital transformation, private label products, and growth strategies, to offer its customers a comprehensive package of services. The combination of innovative products and services, a strong presence throughout Brazil, and forward-thinking leadership makes Raia Drogasil SA one of the leading healthcare companies in Brazil. Answer: Raia Drogasil SA is a leading Brazilian retail company specializing in the sale of pharmaceuticals and health products. Its business model includes divisions for medications, health insurance, pharmacies, digital transformation, private label products, and growth strategies. The company aims to meet the growing needs of customers for health products and services through innovative offerings and a strong presence throughout Brazil.
odotettu liikevaihto Raia Drogasil S/A on 46,03 Mrd. BRL. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Raia Drogasil S/A on 1,46 Mrd. BRL. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Raia Drogasil S/A:n hinta-voitto-suhde (P/E) on tällä hetkellä 24,91. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Raia Drogasil S/A-osakkeen arvostusta.
Raia Drogasil S/A:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,79. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Raia Drogasil S/A-osakkeen arvostuskennuslukuna.
Raia Drogasil S/A:n Eulpool-laatuscore on 8/10.
Raia Drogasil S/A:n ISIN on BRRADLACNOR0. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Raia Drogasil S/A:n ticker on RADL3.SA. Tämä pörssinoteeraus käytetään Raia Drogasil S/A-osakkeiden kauppaan pörssissä.
Raia Drogasil S/A osake
Raia Drogasil S/A vertaisryhmä
Raia Drogasil S/A Ticker
Raia Drogasil S/A FIGI
Kaikki tunnusluvut ja syvällinen analyysi Raia Drogasil S/A:sta
Meidän osakeanalyysimme Raia Drogasil S/A-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Raia Drogasil S/A:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: